Acadia Pharma Must Face Investors' Drug Approval Claims
By Emilie Ruscoe · June 10, 2026, 3:35 PM EDT
Acadia Pharmaceuticals must face investors' class action claims it misstated the likelihood that it would get regulatory approval to market its psychosis drug pimavanserin for expanded use, a California federal judge...
To view the full article, register now.